Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma - Wikidata - wikimedia - TriplyDB

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

http://www.wikidata.org/entity/Q33381498

about

Molecular and therapeutic potential and toxicity of valproic acid Epigenetic treatment of solid tumours: a review of clinical trials Molecular Targeted Therapies of Aggressive Thyroid Cancer Internal radiation therapy: a neglected aspect of nuclear medicine in the molecular era Medical management of metastatic medullary thyroid cancer Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer Clinical Toxicities of Histone Deacetylase Inhibitors.Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update Alternative medical treatment for radioiodine-refractory thyroid cancers.Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Interpreting clinical assays for histone deacetylase inhibitors.Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.Thyroid cancer: emerging role for targeted therapies.Targeted treatment of differentiated and medullary thyroid cancer.Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.New therapies for dedifferentiated papillary thyroid cancer Standard and emerging therapies for metastatic differentiated thyroid cancer.Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.Epigenetics modifications and therapeutic prospects in human thyroid cancer.Thyroid cancer: pathogenesis and targeted therapy New insight into the treatment of advanced differentiated thyroid cancer.Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience Epigenetics in cancer stem cells.Romidepsin: a novel histone deacetylase inhibitor for cancer.Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.Pharmacotherapy options for advanced thyroid cancer: a systematic review.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Targeting histone deacetylase in thyroid cancer.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

P2860

Q21296867-20806ED0-0E4E-428B-9A06-BD5638728878 Q26773803-77C0A9E4-C85D-4C0C-939E-8FAAF5D30B64 Q26774734-47C198D8-B128-49D5-AE3B-7EDB871B68D2 Q26786554-F9E6474F-F8D1-44B0-B6D9-ED30F0C4325D Q27005897-F1D80F05-C8B5-4147-9EDD-2F719E2A672B Q28547158-941510F9-593A-4193-BD0F-2312D2D9294F Q31135325-A71FFE98-E5B3-4B5F-97DA-5DD8730BCA84 Q33399121-F99DBE97-E052-4833-9F80-EC79F55C3B66 Q33437948-802AB74A-E43C-4640-868F-4840EB6C1F9C Q33587821-312CBC1D-D738-4080-B330-66A07C40CF56 Q33704599-FB3C5097-8DE5-4970-B5A1-58458F507DE0 Q33736109-9028D571-7622-48F5-8008-9A2FE63594A5 Q33829390-EF602FB2-CF29-45BE-9B4F-F29112AFE173 Q35003657-2C817166-E1DA-4A75-AE33-6E662F14DE4C Q35023367-42A16149-5A0C-4585-8B8D-C6040297DE37 Q35076227-16080E2E-9D45-490C-AC73-4B76FC3DBFB9 Q35147151-11CAFE84-9BA8-470E-AB7D-E548B634BAB5 Q35246513-3E9963C4-48B6-4E82-9BDC-6D0AF7B4D9A6 Q35381593-AF2C4051-71E5-4529-8C4A-8C0B2D1383C0 Q35583906-D384F30D-A1FE-4DE3-BC16-F348F598DB42 Q35628323-79361E52-1384-42F0-9187-CC7E733AD4FE Q35971504-C2A49673-D43B-4FAC-9DF6-85EB62705049 Q36328045-A8D80768-BE1C-430A-9BBC-9F7C5F06A470 Q36528466-2E698255-3DD2-432C-9E25-E4A841340608 Q36715993-85721EA0-3A55-4F17-A823-2383EBD167A2 Q36813563-8BDD5288-33BB-40F0-AB96-A4414EBCEA80 Q37092508-4DD37125-669A-4345-B9D1-69CDDA81E74E Q37123127-F29CEE9D-73A4-4190-BB92-289C14179974 Q37226511-F8518497-C771-4F49-88EC-948293F7D262 Q37297635-3AD1CDC6-61F2-4153-8F9D-D16D61E1F051 Q37330090-4EE8EF60-77F7-4C88-ACDA-38B99526C697 Q37417441-E6747209-864A-41A9-958E-4DF609E692AE Q37618640-78C8BE60-8040-4648-B11E-D5FB79830C77 Q37893664-9115904B-B3FE-4B02-9573-2BEA96839C23 Q37902054-51CF716F-3938-47B6-A2CB-3C941D0E7574 Q37970758-B2C2CEAB-C5A9-4413-9B0E-031C8E1A7028 Q37988566-0CFA86ED-B367-4D9A-83F5-791D27F4C9EA Q37993589-B324361C-709B-4C52-B406-7766A4536803 Q38066990-0E3B84A3-E382-4797-914E-87834FF085C1 Q38081988-9C284C2B-6BE7-413C-9AC9-4F9D0AF6890A

P2860

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

http://www.wikidata.org/entity/Q33381498

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@ast

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@en

type

label

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@ast

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@en

prefLabel

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@ast

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@en

P1433

Q33381498-EA89F261-3B1B-4069-83AA-6151FE9C2A38

P1476

Q33381498-24E52270-7A1D-43C6-83E5-C4DD42FDFE2B

P2093

Q33381498-1A233EA1-D7D3-40A6-8330-B3FB9EDE4396

Q33381498-2F57D3F3-D487-46B0-B294-CFCF04440805

Q33381498-4B73EC6A-F0CF-47C7-9051-D5591C46D64A

Q33381498-72D94F12-199B-448F-AB19-F8FF0C432A14

Q33381498-86137DB2-1833-4C87-90A0-D9113DB1449D

Q33381498-9419CEAB-53FD-4D06-97E1-BBB4F2E843AC

Q33381498-97AF18FB-3288-48BA-BAE9-5FFF54525EFA

Q33381498-DC8E474F-C55F-4120-9F2C-5E52C0940E10

Q33381498-F765AE05-D595-4E8A-8C5B-0DAE1C722A03

P2860

Q33381498-02C11B94-8407-4F1C-94D1-A15077CB16E3

Q33381498-0DA6ABD1-3AAA-4FB6-B700-F338F6A307ED

Q33381498-0FED0320-23E7-4887-8EDC-82CC0B226001

Q33381498-12E7EF34-59EA-4D57-995E-3ACF2EA22A1A

Q33381498-14EBCB6F-E9B2-47C9-8483-7336FD9677EC

Q33381498-2007CA52-600C-4FBC-A456-7F14AD67D1A1

Q33381498-382CE00A-DDA9-4D62-BAD4-7EBDFFD046D0

Q33381498-39D46425-3FDC-4048-A952-05904389D022

Q33381498-45B6EA38-8F64-4DC4-8A5F-ADCD348D2BCB

Q33381498-560646E5-768D-4FE2-B511-B5D0A37B06FD

P304

Q33381498-15B18DE1-9DC4-436C-8349-8BC1ED6D9368

P31

Q33381498-04542A17-1180-4C32-AF8C-8C56838130C3

P356

Q33381498-3C52FB71-A057-46DC-A191-F71AD52541C8

P407

Q33381498-D9EFF59D-5DDA-4552-88F6-3D298125A63B

P433

Q33381498-C8AEB958-7C15-4DD2-BC41-BFDF99752703

P478

Q33381498-2242F991-44E7-450B-8C0E-DD51BF3D47F7

P577

Q33381498-5011A11C-8DD1-43A4-A467-35568B059AEC

P5875

Q33381498-E17170BB-EA99-436B-AD78-AC1290F44E62

P698

Q33381498-77F52AFE-9F3A-410B-AF4D-B27E94A79917

P921

Q33381498-36A2FD36-A5B1-47A0-A323-B813A1415C92

P932

Q33381498-FF31A6EA-CD11-4E20-8281-D889C084948E

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Lack of therapeutic effect of ...... e-refractory thyroid carcinoma

@en

P2093

Daria Arbogast

http://www.w3.org/2001/XMLSchema#string

James A Zwiebel

http://www.w3.org/2001/XMLSchema#string

Jennifer A Woyach

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

Matthew D Ringel

http://www.w3.org/2001/XMLSchema#string

Michael Grever

http://www.w3.org/2001/XMLSchema#string

Miguel Villalona-Calero

http://www.w3.org/2001/XMLSchema#string

Minden Collamore

http://www.w3.org/2001/XMLSchema#string

Richard T Kloos

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

The fundamental role of epigenetic events in cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Alteration of nucleosome structure as a mechanism of transcriptional regulation

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status.

P304

164-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2008-1631

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23316889

http://www.w3.org/2001/XMLSchema#string

P698

18854394

http://www.w3.org/2001/XMLSchema#string

P921

P932

2630867

http://www.w3.org/2001/XMLSchema#string